FDA Clearance Tracker · P230023-S010
GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis
Last checked: Nov 20, 2026Latest source record: Jan 15, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Jan 15, 2026
Approved
Time to decision
153 days
Received Aug 15, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P230023-S010
- Device name
- GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis
- Applicant
- W. L. Gore & Associates, Inc.
- Applicant location
- Flagstaff, AZ
- Received
- Aug 15, 2025
- Decided
- Jan 15, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P230023
Device type
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
approval of the revised protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P230023.
Source documents
Other decisions for W. L. Gore & Associates, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- GORE® VIABAHN® VBX Balloon Expandable EndoprosthesisPMA supplement
P160021-S051 · Decided Oct 8, 2026 · 244 days after receipt · Panel Track
Device type: Iliac covered stent, arterial (PRL) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.